| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/14740338.2015.1089231 |
| P698 | PubMed publication ID | 26461271 |
| P2093 | author name string | Agnes L F Chan | |
| Henry W C Leung | |||
| P2860 | cites work | Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 |
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials | Q33293618 | ||
| Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial | Q33724456 | ||
| Risk of cardiovascular adverse events from trastuzumab (Herceptin(®)) in elderly persons with breast cancer: a population-based study. | Q34049037 | ||
| Epidemiology of breast cancer in older women: implications for future healthcare | Q34458444 | ||
| A case-control study of reproductive factors associated with subtypes of breast cancer in Northeast China | Q34612076 | ||
| Adjuvant trastuzumab in HER2-positive breast cancer | Q35710898 | ||
| Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study | Q36207305 | ||
| Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epider | Q36339698 | ||
| Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring | Q37123487 | ||
| Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials | Q37202470 | ||
| Trastuzumab-related cardiotoxicity among older patients with breast cancer | Q37289617 | ||
| Characteristics and prognosis for molecular breast cancer subtypes in Chinese women | Q37526723 | ||
| Risk of cardiac dysfunction with trastuzumab in breast cancer patients: A meta-analysis | Q37800698 | ||
| Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trials. | Q38006133 | ||
| Significant difference in the trends of female breast cancer incidence between Taiwanese and Caucasian Americans: implications from age-period-cohort analysis | Q38472519 | ||
| Molecular subtypes of breast cancer emerging in young women in Taiwan: evidence for more than just westernization as a reason for the disease in Asia | Q42455037 | ||
| Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. | Q42626922 | ||
| HER2 ASCO guidelines. The answer to everything? | Q42925491 | ||
| Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998–2005 | Q44868340 | ||
| HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues | Q47612892 | ||
| 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. | Q53243856 | ||
| Coming of age: breast cancer in seniors. | Q54614592 | ||
| Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors | Q58614608 | ||
| Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer | Q58849554 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | meta-analysis | Q815382 |
| P304 | page(s) | 1661-1671 | |
| P577 | publication date | 2015-10-13 | |
| P1433 | published in | Expert Opinion on Drug Safety | Q5421206 |
| P1476 | title | Trastuzumab-induced cardiotoxicity in elderly women with HER-2-positive breast cancer: a meta-analysis of real-world data | |
| P478 | volume | 14 |
| Q39303131 | Cardio-oncology in the older adult. |
| Q37735969 | Cardioprotective Effect of Dexrazoxane in Patients with HER2-Positive Breast Cancer Who Receive Anthracycline Based Adjuvant Chemotherapy Followed by Trastuzumab |
| Q93001734 | Diastolic dysfunction can precede systolic dysfunction on MUGA in cancer patients receiving trastuzumab-based therapy |
| Q92533204 | HER2+ breast cancer treatment and cardiotoxicity: monitoring and management |
| Q48127710 | Pharmacotherapeutic Management of Breast Cancer in Elderly Patients: The Promise of Novel Agents. |
| Q53463994 | Population PBPK modelling of trastuzumab: a framework for quantifying and predicting inter-individual variability. |
| Q48308202 | Risk of gastrointestinal complications in breast cancer patients treated with neratinib: a meta-analysis. |
| Q48056637 | The real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu-positive early breast cancer in Taiwan |
| Q98289888 | Trastuzumab increases pulmonary vein arrhythmogenesis through modulating pulmonary vein electrical and conduction properties via phosphatidylinositol 3-kinase signaling |
Search more.